In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: Comparison with ciprofloxacin, levofloxacin, and gatifloxacin

Japanese Journal of Antibiotics

Volumn 55, Issue 6, 2002, Pages 791-799

  Shimizu, Masaki ^a   Tabata, Makiko ^a   Hara, Tetsuro ^a   Araake, Minako ^a   Watanabe, Hiroomi ^a   Nishino, Takeshi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORO 1 METHYL 4 OXO 7 (1 PIPERAZINYL) 4H 1,3 THIAZETO[3,2 A]QUINOLINE 3 CARBOXYLIC ACID; CIPROFLOXACIN; DRUG METABOLITE; GATIFLOXACIN; LEVOFLOXACIN; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL CELL; BACTERICIDAL ACTIVITY; BIOACCUMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0036956052     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. ITO, A.; K. HIRAI, M. INOUE, et al.: In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob. Agents Chemother. 17(2): 103-108, 1980
2. SATO, K.; Y. MATSUURA, M. INOUE, et al.: In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob. Agents Chemother. 22(4): 548-553, 1982
3. WISE, R.; J. M. ANDREWS & L. J. EDWARDS: In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 23(4): 559-564, 1983
4. FUJIMAKI, K.; T. NOUMI, I. SAIKAWA, et al.: In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob. Agents Chemother. 32(6): 827-833, 1988
5. DENIS, A. & N. J. MOREAU: Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition. J. Antimicrob. Chemother. 32(3): 379-392, 1993
6. CHAPMAN, J. S. & N. H. GEOROGOPAPADAKOU: Routes of quinolone permeation in Escherichia coli. Antimicrob. Agents Chemother. 32(4): 438-442, 1988
7. LEI, Y.; K. SATO & T. NAKAE: Ofloxacin-resistant Pseudomonas aeruginosa mutants with elevated drug extrusion across the inner membrane. Biochem. Biophys. Res. Commun. 178(3): 1043-1048, 1991
8. McCAFFREY, C.; A. NERTASSO, J. PACE, et al.: Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Antimicrob. Agents Chemother. 36(8): 1601-1605, 1992
9. Chemoteraphy 29: 76-79, 1981
10. PIDDOCK, L. J. V.; Y.-F. JIN, V. RICCI, et al.: Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 43(1): 61-70, 1999
11. TAKEI, M.; H. FUKUDA, R. KISHII, et al.: Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45(12): 3544-3547, 2001
12. DRLICA, K. & X. ZHAO: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61(3): 377-392, 1997
13. HIRAI, K.; H. AOYAMA, T. IRIKURA, et al.: Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob. Agents Chemother. 29(3): 535-538, 1986
14. TAKENOUCHI, T.; F. TABATA, Y. IWATA, et al.: Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 40(8): 1835- 1842, 1996
15. PIDDOCK, L. J. V.; Y. F. JIN & D. J. GRIGGS: Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus. J. Antimicrob. Chemother. 47(3): 261-270, 2001
16. PIDDOCK, L. J. V. & M. M. JOHNSON: Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46(3): 813-820, 2002